Abivax SA (ABVX) vs Edgewise Therapeutics (EWTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Abivax SA (ABVX) over the past year, gaining 155.6% versus a gain of 2.9%. Abivax SA is the larger company by market cap ($7.77 billion vs $4.26 billion), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | EWTX |
|---|---|---|
| Share price | $89.05 | $39.23 |
| Market cap | $7.77B | $4.26B |
| 1-day change | +2.34% | -0.86% |
| YTD return | -33.97% | +58.09% |
| 1-year return | +2.94% | +155.57% |
| 5-year return | — | +121.14% |
| EPS (TTM) | $-6.08 | $-1.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-167.79M |
| 52-week high | $148.83 | $48.51 |
| 52-week low | $69.81 | $14.25 |
| Distance from 52-week high | -40.17% | -19.13% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +84.17% | +34.13% |
| Average volume | 1.11M | 1.34M |
| Shares outstanding | 87.27M | 108.60M |
| Employees | 98 | 127 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed ABVX by 152.6 percentage points over the past year.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Healthcare · Biotechnology · 98 employees
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Healthcare · Biotechnology · 127 employees
ABVX vs EWTX FAQ
Which is bigger, Abivax SA or Edgewise Therapeutics?
Abivax SA (ABVX) is larger, with a market capitalization of $7.77B compared with $4.26B for Edgewise Therapeutics (EWTX).
Which stock has performed better over the past year, ABVX or EWTX?
EWTX returned +155.57% over the past 12 months, compared with +2.94% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Edgewise Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.